Skip to main
  1. Stocks
  2. CAI
  3. Forecast
CAI

CAI (CAI) Stock Forecast & Price Target

CAI (CAI) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 30%
Hold 30%
Sell 0%
Strong Sell 0%

Bulls say

Caris Life Sciences is supported by a leading precision-oncology platform with strong underlying demand, as Q3'26 revenue of $275M rose 27% Y/Y, Adj. EBITDA reached $44M, and cash stood at $769M while volumes climbed to 61.5k cases and blended ASPs improved to about $4,272 per test. Its outlook is strengthened by durable share gains in a market still under-penetrated at roughly 30%, expanded payer coverage, and a large sales force of 325 that should keep supporting case growth and mix-shift toward higher-reimbursed tests like MI Cancer Seek. Additional upside comes from pipeline catalysts including Caris Confirm MRD launching in December and Caris Detect entering early screening, while a raised 2026 revenue guide of $1.04B-$1.05B and a path to stronger ASPs reinforce operating leverage.

Bears say

Caris Life Sciences is facing a challenging fundamental setup because slower-than-expected revenue contribution from Caris Assure and broader competitive pressure in precision oncology could limit near-term growth, especially against large established rivals in tissue, blood, MRD, and screening diagnostics. Reimbursement and contracting remain uncertain, while the company’s newer products carry commercialization risk despite its successful tissue test history; its early Detect launch looks particularly fragile at $3,500 per test with no insurance coverage, no FDA clearance, and a small, high-risk study base of just above 3,000 participants. It also faces valuation volatility, potential litigation, and modest balance sheet risk if additional capital is needed to fund expansion into MRD and early cancer detection.

CAI (CAI) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 30% recommend Buy, 30% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CAI and is not a guaranteed prediction by Public.com or investment advice.

CAI (CAI) Analyst Forecast & Price Prediction

Get the latest CAI (CAI) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CAI (CAI)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CAI (CAI) Forecast

Analysts have given CAI (CAI) a Buy based on their latest research and market trends.

According to 10 analysts, CAI (CAI) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CAI (CAI)


CAI (CAI) Analyst Forecast & Price Prediction

Get the latest CAI (CAI) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CAI (CAI)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CAI stock data and trends